Comparison of Abciximab treatment for percutaneous coronary intervention (PCI) with other antiplatelet therapies.
| Entry Condition . | Treatment Duration (mo.) . | Number Benefitted per 1,000 Treated . |
|---|---|---|
| Acute MI | 1 | 38±5 |
| Prior MI* | 27 | 36±6 |
| Primary Prevention* | 62 | 4±3 |
| PCI** (Abciximab) | 0.017 | 58 |
| Abbreviations: PCI, percutaneous coronary intervention. | ||
| Entry Condition . | Treatment Duration (mo.) . | Number Benefitted per 1,000 Treated . |
|---|---|---|
| Acute MI | 1 | 38±5 |
| Prior MI* | 27 | 36±6 |
| Primary Prevention* | 62 | 4±3 |
| PCI** (Abciximab) | 0.017 | 58 |
| Abbreviations: PCI, percutaneous coronary intervention. | ||
Data from Antiplatelet Trialists' Collaboration (Br Med J 308: 1540, 1994) Other antiplatelet therapies included primarily aspirin alone or in combination with dipyridamole. Other regimens included ticlopidine, sulphinpyrazone, dypiridamole, aspirin and sulphinpyrazone, and suloctidil. Data include results from 145 trials involving approximately 100,000 patients.
Data from EPITSTENT: 30-day event rates (Lancet 352:87, 1998)